Comprehensive Guide to Ustekinumab: Uses, Dosage, Side Effects, and More

1. What is Ustekinumab?

2. Overview of Ustekinumab

Generic Name

Ustekinumab

Brand Name

Stelara, generics

Drug Group

IL-12/23 inhibitor (biologic, immunosuppressant)

Commonly Used For

This medication is used to:

• Treat plaque psoriasis.
• Manage psoriatic arthritis.
• Control Crohn’s disease and ulcerative colitis.

Key Characteristics

• Form: Subcutaneous injection (45 mg/0.5 mL, 90 mg/0.5 mL, 130 mg/26 mL for IV induction) (detailed in Dosage section).
• Mechanism: Binds to the p40 subunit of IL-12 and IL-23, reducing T-cell activation and inflammation.
• Approval: FDA-approved (2009 for Stelara) and EMA-approved for multiple indications.

3. Indications and Uses of Ustekinumab

Ustekinumab is indicated for a range of autoimmune and inflammatory conditions, leveraging its immunomodulatory effects:

• Moderate to Severe Plaque Psoriasis: Treats adults and children (6+ years) with psoriasis affecting ≥10% body surface area or causing significant impairment, reducing plaques and scaling, supported by long-term clinical trials like PHOENIX and ACCEPT.
• Psoriatic Arthritis: Manages joint inflammation, enthesitis, and dactylitis in adults and children (6+ years), improving physical function, per rheumatology guidelines.
• Crohn’s Disease: Treats moderate to severe Crohn’s disease in adults and children (6+ years) unresponsive to conventional therapy, inducing and maintaining remission, with evidence from UNITI-1 and UNITI-2 studies.
• Ulcerative Colitis: Controls moderate to severe ulcerative colitis in adults, reducing mucosal inflammation and achieving clinical response, supported by UNIFI trial data.
• Ankylosing Spondylitis: Investigated off-label for ankylosing spondylitis, reducing spinal inflammation and stiffness, with emerging rheumatology research.
• Hidradenitis Suppurativa: Explored off-label to manage hidradenitis suppurativa, decreasing abscesses and nodules, with dermatologic study support.
• Behçet’s Disease: Used off-label to control ocular and mucocutaneous manifestations in Behçet’s disease, improving quality of life, noted in rheumatologic case studies.
• Juvenile Idiopathic Arthritis (JIA): Investigated off-label for JIA subtypes with enthesitis, enhancing joint mobility, with pediatric rheumatology data.
• Non-Radiographic Axial Spondyloarthritis: Managed off-label to reduce inflammation in early axial spondyloarthritis, with promising results from spondylitis research.
• Psoriasis-Associated Comorbidities: Employed off-label to address psoriatic comorbidities like metabolic syndrome, improving cardiovascular risk factors, supported by dermatologic-endocrinology studies.

Note: This drug requires screening for infections and tuberculosis; consult a healthcare provider for individualized treatment plans.

4. Dosage of Ustekinumab

Important Note: The dosage of this IL-12/23 inhibitor must be prescribed by a healthcare provider. Dosing varies by indication, weight, and response, with adjustments based on clinical evaluation.

Dosage for Adults

• Plaque Psoriasis:
  • Initial: 45 mg or 90 mg SC at weeks 0, 4, then every 12 weeks (90 mg for >100 kg).
  • Maintenance: Continue every 12 weeks.
• Psoriatic Arthritis:
  • Same as psoriasis: 45 mg or 90 mg SC at weeks 0, 4, then every 12 weeks.
• Crohn’s Disease:
  • Initial: 260–520 mg IV (based on weight: ≤55 kg: 260 mg; 55–85 kg: 390 mg; >85 kg: 520 mg) at week 0, then 90 mg SC at week 8.
  • Maintenance: 90 mg SC every 8 weeks.
• Ulcerative Colitis:
  • Initial: 260–520 mg IV (weight-based) at week 0, then 90 mg SC at week 8.
  • Maintenance: 90 mg SC every 8 weeks.

Dosage for Children

• 6–17 years (Plaque Psoriasis, Psoriatic Arthritis, Crohn’s Disease):
  • <60 kg: 0.75 mg/kg SC at weeks 0, 4, then every 12 weeks.
  • 60–100 kg: 45 mg SC at weeks 0, 4, then every 12 weeks.

  • 100 kg: 90 mg SC at weeks 0, 4, then every 12 weeks, under pediatric specialist supervision.

  • Not recommended under 6 years.

Dosage for Pregnant Women

• Pregnancy Category B: Limited data; use only if benefits outweigh risks. Consult an obstetrician, with fetal monitoring.

Dosage Adjustments

• Renal Impairment: No adjustment needed; monitor in severe cases (CrCl <30 mL/min).
• Hepatic Impairment: No specific adjustment; use caution in severe cases (Child-Pugh C).
• Elderly: Start with 45 mg; increase to 90 mg if tolerated.
• Concomitant Immunosuppressants: Adjust if combined with other biologics, increasing infection risk.

Additional Considerations

• Administer this active ingredient via SC injection or IV infusion (for induction) by a healthcare provider or trained patient.
• Rotate injection sites to prevent irritation.

5. How to Use Ustekinumab

• Administration:
  • For SC: Inject into thigh, abdomen (avoid 2 inches around navel), or upper arm using a prefilled syringe/pen; rotate sites.
  • For IV: Administer over at least 1 hour via infusion pump in a controlled setting.
  • Take with or without food (oral not applicable).
• Timing: Follow the initial loading doses (weeks 0, 4), then maintenance every 8–12 weeks as directed.
• Monitoring: Watch for injection site reactions, fever, or signs of infection (e.g., cough).
• Additional Tips:
  • Store at 2–8°C (36–46°F); do not freeze or shake.
  • Keep out of reach of children due to injection risk.
  • Report severe redness, swelling, or signs of allergic reaction immediately.

6. Contraindications for Ustekinumab

This drug is contraindicated in:

• Hypersensitivity: Patients with a known allergy to Ustekinumab or its components.
• Active Tuberculosis: Contraindicated until treated.
• Severe Infections: Avoid during active severe infections (e.g., sepsis).
• Pregnancy: Contraindicated unless life-saving (case-by-case).

7. Warnings & Precautions for Ustekinumab

General Warnings

• Infections: Risk of serious infections (e.g., tuberculosis, fungal); screen and monitor regularly.
• Malignancies: Increased risk of lymphoma and skin cancer; perform skin checks.
• Hypersensitivity Reactions: Risk of anaphylaxis or serum sickness; discontinue if severe.
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Rare neurological event; monitor symptoms.
• Immunizations: Avoid live vaccines during therapy.

Additional Warnings

• Hepatotoxicity: Rare liver enzyme elevation; monitor in chronic use.
• Cardiovascular Events: Increased risk in patients with prior heart disease; assess regularly.
• Neurological Effects: Rare demyelinating disorders; report numbness or vision changes.
• Allergic Reactions: Injection site or systemic reactions; manage with antihistamines if mild.
• Bone Marrow Suppression: Rare; monitor blood counts in long-term use.

Use in Specific Populations

• Pregnancy: Category B; use only if essential with fetal monitoring.
• Breastfeeding: Excreted in breast milk; monitor infant for effects.
• Elderly: Higher risk of infections; start with lower doses.
• Children: Limited to 6+ years; supervise closely.
• Renal/Hepatic Impairment: Use caution; avoid in severe cases.

Additional Precautions

• Inform your doctor about infections, cancer history, or medication history before starting this medication.
• Avoid abrupt cessation; taper if combined with other immunosuppressants.

8. Overdose and Management of Ustekinumab

Overdose Symptoms

Overdose may cause:

• Injection site reactions, fatigue, or mild fever.
• Severe cases: Severe infections, anaphylaxis, or neurological symptoms.
• Headache, nausea, or rash as early signs.
• Respiratory distress with extremely high doses.

Immediate Actions

• Contact the Medical Team: Seek immediate medical help.
• Supportive Care: Administer IV fluids, monitor vital signs, and treat infections or allergic reactions.
• Specific Treatment: No antidote; manage symptoms and monitor organ function.
• Monitor: Check infection markers, liver function, and neurological status for 24–48 hours.

Additional Notes

• Overdose risk is low; store securely.
• Report persistent symptoms (e.g., severe headache, fever) promptly.

9. Side Effects of Ustekinumab

Common Side Effects

• Upper Respiratory Infections (10–15%, manageable with rest)
• Headache (5–12%, relieved with hydration)
• Fatigue (4–10%, decreases with tolerance)
• Injection Site Reactions (3–8%, reduced with rotation)
• Nausea (2–6%, improved with food)
  These effects may subside with dose adjustment.

Serious Side Effects

Seek immediate medical attention for:

• Infectious: Tuberculosis, fungal infections, or sepsis.
• Malignancies: Lymphoma, skin cancer, or other neoplasms.
• Neurological: RPLS, demyelinating disorders, or seizures.
• Hepatic: Jaundice or liver failure.
• Allergic: Rash, angioedema, or anaphylaxis.

Additional Notes

• Regular monitoring for infections, liver function, and skin changes is advised.
• Report any unusual symptoms (e.g., persistent cough, vision changes) immediately to a healthcare provider.

10. Drug Interactions with Ustekinumab

This active ingredient may interact with:

• Live Vaccines: Reduces immune response; avoid.
• Immunosuppressants: Increases infection risk (e.g., methotrexate); monitor.
• CYP450 Substrates: Minimal effect; monitor levels if critical (e.g., warfarin).
• Antibiotics: May alter infection prophylaxis; adjust timing.
• Corticosteroids: Enhances immunosuppression; use cautiously.

Action: Provide your healthcare provider with a complete list of medications.

11. Patient Education or Lifestyle

• Medication Adherence: Take this IL-12/23 inhibitor as prescribed for autoimmune conditions, following the exact schedule.
• Monitoring: Report infections, skin changes, or fatigue immediately.
• Lifestyle: Avoid live vaccines; maintain good hygiene.
• Diet: Take with or without food (SC); stay hydrated to support immunity.
• Emergency Awareness: Know signs of severe infection or allergic reaction; seek care if present.
• Follow-Up: Schedule regular check-ups every 3–6 months to monitor disease activity, infections, and liver health.

12. Pharmacokinetics of Ustekinumab

• Absorption: Well-absorbed SC (peak at 7–14 days); IV achieves steady state faster.
• Distribution: Volume of distribution ~0.16 L/kg; minimal tissue penetration.
• Metabolism: Degraded via proteolysis into small peptides, no hepatic metabolism.
• Excretion: Primarily cleared via the reticuloendothelial system; half-life 15–46 days (dose-dependent).
• Half-Life: 15–46 days, with sustained anti-inflammatory effects.

13. Pharmacodynamics of Ustekinumab

This drug exerts its effects by:

• Neutralizing IL-12 and IL-23, inhibiting Th1 and Th17 cell differentiation.
• Reducing pro-inflammatory cytokines (e.g., TNF-α, IL-17) in autoimmune diseases.
• Demonstrating dose-dependent efficacy in psoriasis and IBD, with prolonged action.
• Exhibiting a favorable safety profile compared to older immunosuppressants.

14. Storage of Ustekinumab

• Temperature: Store at 2–8°C (36–46°F); do not freeze or shake.
• Protection: Keep in original carton, away from light.
• Safety: Store in a locked refrigerator out of reach of children.
• Disposal: Dispose of used syringes per sharps regulations or consult a pharmacist.

15. Frequently Asked Questions (FAQs)

Q: What does Ustekinumab treat?
A: This medication treats psoriasis, psoriatic arthritis, Crohn’s, and ulcerative colitis.

Q: Can this active ingredient cause infections?
A: Yes, infections may occur; report persistent symptoms.

Q: Is Ustekinumab safe for children?
A: Yes, for 6+ years with a doctor’s guidance.

Q: How is this drug taken?
A: Via SC injection or IV infusion, as directed.

Q: How long is Ustekinumab treatment?
A: Long-term for chronic conditions with monitoring.

Q: Can I use Ustekinumab if pregnant?
A: Yes, with caution; consult a doctor.

16. Regulatory Information

This medication is approved by:

• U.S. Food and Drug Administration (FDA): Approved in 2009 (Stelara) for psoriasis, expanded to psoriatic arthritis, Crohn’s, and ulcerative colitis.
• European Medicines Agency (EMA): Approved for multiple indications.
• Other Agencies: Approved globally for autoimmune diseases; consult local guidelines.

17. References

1. U.S. Food and Drug Administration (FDA). (2023). Stelara (Ustekinumab) Prescribing Information.
   • Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
2. European Medicines Agency (EMA). (2023). Ustekinumab Summary of Product Characteristics.
   • EMA’s comprehensive information on the medication’s indications and precautions in Europe.
3. National Institutes of Health (NIH). (2023). Ustekinumab: MedlinePlus Drug Information.
   • NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
4. World Health Organization (WHO). (2023). WHO Guidelines on Immunomodulators: Ustekinumab.
   • WHO’s considerations for Ustekinumab in autoimmune therapy.
5. Journal of the American Academy of Dermatology. (2022). Ustekinumab in Psoriasis Management.
   • Peer-reviewed article on Ustekinumab efficacy (note: access may require a subscription).